09/19/23 8:00 AMNasdaq : CRBP conferencesclinical triallow floatCorbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsCorbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023..RHEA-AIneutral
08/08/23 8:00 AMNasdaq : CRBP earningslow floatCorbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateCRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 Preliminary clinical PK data indicates CRB-701 has a longer half-life and reduced levels of circulating free MMAE relative to published data for PADCEV ® CRB-601 IND submission is on track for Q4 2023.RHEA-AIneutral
07/31/23 8:00 AMNasdaq : CRBP conferenceslow floatCorbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology ConferenceCorbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.. BTIG Virtual Biotechnology...RHEA-AIneutral
06/26/23 8:00 AMNasdaq : CRBP low floatCorbus Pharmaceuticals Set to Join Russell Microcap® IndexCorbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that the Company is set to join the Russell Microcap ® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today, as part of the 2023 Russell indexes reconstitution.RHEA-AIneutral
05/31/23 8:00 AMNasdaq : CRBP conferenceslow floatCorbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare ConferenceCorbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023. Management will also be available for one-on-one investor...RHEA-AIneutral
05/09/23 8:00 AMNasdaq : CRBP earningslow floatCorbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateCompany expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate from CSPC Pharmaceutical Group CRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer...RHEA-AIneutral
05/01/23 8:00 AMNasdaq : CRBP conferencesclinical triallow floatCorbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy MeetingCorbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences' 2023 Frontiers in Cancer Immunotherapy meeting,...RHEA-AIneutral
04/18/23 8:00 AMNasdaq : CRBP low floatCorbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old TargetCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that the Company will host the first in the seriesRHEA-AIneutral
04/17/23 8:30 AMNasdaq : CRBP clinical triallow floatCorbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual MeetingCRB-601 shows dose-dependent antitumor activity correlating with increased binding to αvβ8 in pre-clinical tumor models CRB-601 enhances anti-PD-1 immunotherapy efficacy and induces long-lasting tumor-specific cytotoxic T-cells IND submission for CRB-601 on track for 2H 2023 NORWOOD, Mass. , AprilRHEA-AIneutral
03/14/23 4:35 PMNasdaq : CRBP low floatCorbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual MeetingCorbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for presentation at a poster at the 2023 American Association for Cancer Research annual meeting, to be held April 14-19, 2023 in Orlando, Fl.. Poster Presentation...RHEA-AIneutral